Mirada Medical uses deep learning technology to develop medical imaging software that improves treatment and care for patients with cancer and other diseases. Its software automates tasks and processes in a range of clinical work, including diagnostic imaging, radiation therapy and interventional oncology, thereby helping to optimise workflows, save time and improve consistency.
The company has developed a range of accessible solutions that easily fit within existing platforms and technologies. Mirada Medical’s products have been installed in over 2,000 hospitals, imaging centres and cancer centres worldwide, supporting clinicians to make better decisions and deliver personalised care. One of its products, developed to optimise treatment for patients undergoing radiotherapy, offers significant time savings when compared to similar technologies.
As Chief Product Officer, Sarah Bond aims to strategically increase revenue and market share through the development of innovative products that will help the company to retain its competitive advantage.
Supported by the SME Leaders Programme, Sarah Bond will have access to workshops, training, mentoring and networking opportunities to help strengthen the skills needed to lead a talented, growing team. This will help her to deliver a complex and ambitious business plan for growth in the rapidly evolving market of artificial intelligence for healthcare.
